Prevention of renal osteodystrophy in peritoneal dialysis

Kidney International

Volumn 54, Issue 6, 1998, Pages 2226-2233

  Weinreich, Thomas ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adynamic bone disease; Metabolic acidosis; Peritoneal dialysis; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

CALCIUM DERIVATIVE; CYTOKINE; GROWTH FACTOR; VITAMIN D;

ACID BASE BALANCE; AGE; CONFERENCE PAPER; DIABETES MELLITUS; DIET SUPPLEMENTATION; HUMAN; KIDNEY FAILURE; METABOLIC ACIDOSIS; ORAL DRUG ADMINISTRATION; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RENAL OSTEODYSTROPHY;

EID: 0031754713     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00182.x     Document Type: Conference Paper

References (64)

1. FASSBINDER W, BRUNNER FP, BRYNGER H, EHRICH JH, GEERLINGS W, RAINE AE, RIZZONI G, SELWOOD NH, TUFVESONG, WING AJ: Combined report on regular dialysis and transplantation in Europe, XX. Nephrol Dial Transplant 11:186-191, 1991
2. DRUEKE T: The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 48:259-272, 1995
3. SALEM MM: Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis 29:862-865, 1997
4. REICHEL H, DRÜEKE T, RITZ E: Skeletal disorders, in Oxford Textbook of Clinical Nephrology (2nd ed), edited by DAVISON AM, CAMERON JS, GRUNFELD JP, KERR DNS, RITZ E, Oxford, Oxford University Press, 1998, pp 1954-1981
5. MUSCI I, HERCZ G: Adynamic bone disease: Pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens 6:356-361, 1997
6. KURZ P, MONIER-FAUGERE MC, BOGNAR B, WERNER E, ROTH P, VLACHOJANNIS J, MALLUCHE H: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861, 1994
7. HUTCHISON AJ, WHITEHOUSE RW, FREEMONT AJ, MAWER EB, GOKAL R: Histological, radiological and biochemical features of the adynamic lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 14:19-29, 1994
8. STANBURY SW, LUMB GA: Parathyroid function in chronic renal failure. A statistical survey of plasma biochemistry in azotemic renal osteodystrophy. Q J Med 35:1-23, 1966
9. BLACK WC, SLATOPOLSKY E, ELKAN I, HOOFSTEN P: Parathyroid morphology in suppressible and nonsuppressible renal hyperparathyroidism. Lab Invest 23:497-509, 1970
10. GOODMAN WG, BELIN T, GALES B, JUPPNER H, SEGRE GV, SALUSKY IB: Calcium-regulated parathyroid hormone release in patients with mild or advanced secondary hyperparathyroidism. Kidney Int 48:1553-1558, 1995
11. INDRIDASON OS, HEATH H, KHOSLA S, YOHAY DA, QUARLES LD: Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int 50:1663-1671, 1996
12. MALBERTI F, CORRADI B, PAGLARDI B, ROMANINI D, GAZO A, SIDOTI A, BARETTA A, BELLAZZI R, IMBASCIATI E: The sigmoidal parathyroid hormone-ionized calcium curve and the set point of calcium in hemodialysis and peritoneal dialysis patients. Perit Dial Int 13:S476-S479, 1993
13. FELSENFELD AJ, RODRIGUEZ M, DUNLAY R, LLACH F: A comparison of parathyroid-gland function in hemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant 6:244-251. 1991
14. WALLFELT CH, LARSSON R, GYLFE E, LJUNGHALL S, RASTAD J, AKERSTÖM G: Secretory disturbance in hyperplastic parathyroid nodules of uremic hyperparthyroidism: Implications for parathyroid autotransplantation. World J Surg 12:4331-438, 1988
15. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35:1049-1056, 1989
16. QUARLES LD, YOHAY DA, CAROLL BA, SPRITZER CE, MINDA SA, BARTHOLOMAY D, LOBAUGH BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparthyroidism in ESRD. Kidney Int 45:1710-1821, 1994
17. FUKAGAWA M, KITAOKA M, YI H, FUKUDA N, MATSUMOTO T, OGATA E, KUROKAWA K: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68:221-228, 1994
18. NAVEH-MANY T, RAHAMIMOV R, LIVNI N, SILVER J: Parathyroid cell proliferation in normal and chronic renal failure rats: The effect of calcium, phosphate and vitamin D. J Clin Invest 96:1786-1793, 1995
19. WANG WL, JOHANSSON H, KRASNICKA T, FARNEBO LH, GRIMELIUS L: Detection of apoptotic cells and expression of K167 antigen, BCL 2, p53 oncoproteins in human parathyroid adenoma. APMIS 104:789-796, 1996
20. ITTEL TH, SCHMITT H, BRANDENBURG V, SIEBERTH HG: Intermittent oral calcitriol and intravenous pamidronat in renal allograft recipients: Divergent effects on hone metabolism and parathyroid function. (abstract) J Am Soc Nephrol 8:575A, 1997
21. GOGUSEV J, DUCHAMBON P, HORY B, GIOVANNI M, GOUREAU Y, SARFATI E, DRÜEKE TB: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51:328-336, 1997
22. FUKUDA N, TANAKA H, TOMINAGA Y, FUKAGAWA M, KUROKAWA K, SEINO Y: Decreased vitamin D receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436-1442, 1993
23. ARNOLD A, BROWN MF, UREÑA P, GAZ RD, SARFATI E, DRÜEKE TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95:2042-2054, 1995
24. HSU CH, PATEL SR: Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: Calcitriol receptor interaction with its target gene in renal failure. Curr Opin Nephrol Hypertens 4:302-306, 1995
25. RODRIGUEZ M, ALMADEN Y, HERNANDEZ A, TORRES A: Effect of phosphate on the parathyroid gland: Direct and indirect? Curr Opin Nephrol Hypertens 5:321-328, 1996
26. 3; Humoral and histomorphometric results. Miner Electrolyte Metab 12:375-382, 1986
27. NORDAL KP, DAHL E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67:929-936, 1988
28. 3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661-669, 1989
29. COEN G, MAZZAFERRO S, BALLANTI P, SARDELLA D, CHICCA S, MANNI M, BONUCCI E, TAGGI F: Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross sectional study. Nephrol Dial Transplant 11:813-819, 1996
30. HAMDY NAT, KANIS JA, BENETON MN, BROWN CB, JUTMANN JR, JORDANS JGM, JOSSE S, MEYRIER A, LINS RL, FAIREY IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Brit Med J 310:358-363, 1995
31. KÜSTER S, SCHMIDT-GAYK H, STEIN G, SCHOLZ C, KRAATZ G, HEIDLAND A: Low dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (a prospective placebo-controlled multicenter trial). Nephrol Dial Transplant 10:2228-2234, 1995
32. COMBE C, MOREL D, DE PRECIGOUT V, BLANCHETTER V, BOUCHET JL, POTAUX L, FOURNIER A, APARICIO M: Long-term control of hyperparathyroidism in advanced renal failure by low phosphorus low protein diet supplemented with calcium (without changes in plasma calcitriol). Nephron 70:287-295, 1995
33. MALLUCHE HM, MONIER-FAUGERE MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int 42(Suppl 38):S62-S67, 1992
34. SHERRARD DJ, OTT SM, MALONEY NA, ANDRESS DL, COBURN JW: The spectrum of bone disease in end-stage renal failure-An evolving disorder. Kidney Int 43:436-442, 1993
35. HERCZ G, PEI Y, GREENWOOD C, MANUEL A, SAIPHOO C, GOODMAN WG, SEGRE GV, FENTON S, SHERRARD DJ: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
36. COUTTENYE MM, D'HAESE: PC, DENG JT, VAN HOOF VO, VERPOOTEN GA, DEBROE ME: High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 12:2144-2150, 1997
37. HERNANDEZ D, CONCEPCIO MT, LORENZO V, MARTINEZ ME, RODRIGUEZ A, DE BONIS E, GONZALEZ-POSADA JM, FELSENFELD AJ, RODRIGUEZ M, TORRES A: Adynamic bone disease with negative aluminum staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 9:517-523, 1994
38. TORRES A, LORENZO V, HERNANDEZ D, RODRIGUEZ JC, CONCEPCION MT, RODRIGUEZ AP, HERNANDEZ A, DE BONIS E, DARIAS E, GONZALEZ-POSADA JM, LOSADA M, RUFINO M, FELSENFELD AJ, RODRIGUEZ M: Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int 47:1434-1442, 1995
39. HUTCHISON AJ, WHITEHOUSE RW, BOULTON HF, ADAMS JE, MAWER EB, FREEMONT TJ, GOKAL R: Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44:1071-1077, 1993
40. HUTCHISON AJ, WHITEHOUSE RW, FREEMONT TJ, ADAMS JE, MAWER EB, GOKAL R: Histological, radiological and biochemical features of the adynamie bone lesion in continuous ambulatory peritoneal dialysis. Am J Nephrol 14:19-29, 1994
41. COUTTENYE MM, D'HAESE PC, VAN HOOF VO, VERPOOTEN GA, DEBROE ME: Low serum levels of alkaline phosphatase of hone origin: A good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant 11:1065-1072, 1996
42. FOURNIER A, YVERNEAU PH, HUE P, SAID S, HAMDINI N, ELDIN HM, MOHAGEB S, OPRISIU R, MARIE A, COHEN SOLAL ME, MORINIERE P: Adynamic bone disease in patients with uremia. Curr Opin Nephrol Hypertens 3:396-410, 1994
43. GOODMAN WG, VEDHUIS JD, RELIUN TR, JUPPNER H, SALUSKY IB: Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism. Kidney Int 51:1590-1595, 1997
44. ANDRESS DL, PANDIAN MR, ENDRES DB, KOPP JB: Plasma insulin-like growth factor and bone formation in uremic hyperparathyroidism. Kidney Int 36:471-477, 1989
45. COEN G, MAZZAFERRO S, BALLANTI P, BONUCCI E, BONDATTI F, PASOUALI M, PERRUZZA I, MANNI M, SARDELLA D: Plasma insulin-like growth factor-1 and bone formation parameters in predialysis chronic renal failure. Miner Electrolyte Metab 17:153-159, 1991
46. SCHMID C: IGFs: Function and clinical importance 2, The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. J Intern Med 234:535-542, 1993
47. WEINREICH T, ZAPF J, SCHMIDT-GAYK H, DELLLING H, REICHEL H: Insulin like growth factor 1 and -2 serum concentration in dialysis patients with various types of renal bone disease. (abstract) J Am Soc Mephrol 8:556A, 1997
48. RITZ E, DEPPISCH R, NAWROTH P: Toxicity of uremia-Does it come of AGE? Nephrol Dial Transplant 9:1-2, 1994
49. ODETTI P, Cosso L, PONZATO MA, DAPINO D, GURERRI G: Plasma advanced glycation end-products in maintenance hemodialysis patients. Nephrol Dial Transplant 10:2110-2113, 1995
50. KORBET SM, MAKITA Z, FIRANEKCA, VLASSARA H: Advanced glcation end products in contiuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 22:588-591, 1993
51. SATO K, ARAKAWA S, TANAKA Y, SUZUKI K, GOTO Y: Bone histomorphometric study of biopsied iliac hone in diabetic patients. J Bone Miner Metab 4:206-213, 1987
52. RICO H, HERNANDEZ ER, CABRANES JA, GOMEZ-CASTRESANA F: Suggestion of a deficient osteoblastic function in diabetes mellitus: The possible cause of osteopenia in diabetics. Calcif Tissue Int 45:71-73, 1989
53. CHERTOW GM, BURKE SK, LAZARUS JM, STENZEL KH, WOMBOLT D, GOLDBERG D, BONVENTRE JV, SLATOPOLSKY E: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
54. BUSHINSKY DA: The contribution of acidosis to renal osteodystrophy. Kidney Int 47:1816-1832, 1995
55. KRAPF R, VETSCH R, VETSCH W, HULTER HN: Chronic metabolic acidosis increases the serum concentration of 1,25-Dihydroxyvitamin D in humans by stimulating its production rate. Critical role of acidosis-induced renal hypophosphatemia. J Clin Invest 90:2456-2463, 1990
56. Lu KC, LIN SH, Yu FC, CHYR SH, SHIEH SD: Influence of metabolic acidosis on serum 1.25(OH)2D3 levels in chronic renal failure. Miner Electrolyte Metab 21:398-402, 1995
57. MORA PALMA FJ, ELLIS HA, COOK DB, DEWAR JH, WARD MK, WILKINSON R, KERR DNS: Osteomalacia in patients with chronic renal failure before dialysis and transplantation. Q J Med 52:332-348, 1983
58. COEN G, MANNI M, ADDARI O, BALLANBTI P, PASQUALI M, CHICCA S, MAZZAFERRO S, NAPOLETANO I, SARDELLA D, BONUCCI E: Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: Effect of calcitriol treatment. Miner Electrolyte Metab 21:375-382, 1995
59. LEFEBVRE A, DE VERNEJOUL MC, GUERIS J, GOLDFARB B, GRAULET AM, MORIEUX C: Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36:1112-1118, 1989
60. GRAHAM KA, HOENICH NA, TARBIT M, WARD MK, GOODSHIP THJ: Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 8:627-631, 1997
61. FERIANI M: Buffers: Bicarbonate, lactate and pyruvate. Kidney Int 50(Suppl 56):S75-S80, 1996
62. FERIANI M, CAROBI C, LA GRECA G, BUONCRISTIANI U, PASSLICKDEETJEN J: Clinical experience with a 39 mmol/l1 bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 17:17-21, 1997
63. BUONCRISTIANI U, GALLI F, ROVIDATTI S, ALBERTINI MC, COVARELLI C, CAROBI C, DI PAOLO N, CANESTRARI F: Bicarbonate versus lactate buffer in peritoneal dialysis solutions: The beneficial effect on RBC metabolism. Perit Dial Int 16:511-518, 1996
64. WEINREICH T: Low or high calcium dialysis solutions in peritoneal dialysis? Kidney Int 50(Suppl 56):S92-S96, 1996